Silencing KRCC1 in the OV90 ovarian cancer cells and in the U2OS osteosarcoma cells significantly increased RPA2 foci formation by ∼6- and 8-fold, respectively, compared to the control cells (Figure 1A and B). Here, RPA2 is linked to ovarian cancer.